| Added by | standudu |
|---|---|
| Last modified by | liaudet-coopman |
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | HER2-positive breast cancer: ¹?F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy |
| Creator | Humbert et al. |
| Author | Olivier Humbert |
| Author | Alexandre Cochet |
| Author | Jean-Marc Riedinger |
| Author | Alina Berriolo-Riedinger |
| Author | Laurent Arnould |
| Author | Bruno Coudert |
| Author | Isabelle Desmoulins |
| Author | Michel Toubeau |
| Author | Inna Dygai-Cochet |
| Author | Séverine Guiu |
| Author | Charles Coutant |
| Author | Pierre Fumoleau |
| Author | François Brunotte |
| Abstract | PURPOSE: To investigate the value of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET/CT) to predict a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. MATERIAL AND METHODS: Fifty-seven consecutive women with HER2-positive breast cancer, treated with trastuzumab plus taxane-based NAC, were prospectively included. Maximum Standardized Uptake Value of the primary tumor and axillary nodes were measured at baseline (PET?.SUVmax) and after the first course of NAC (PET?.SUVmax). Tumor metabolic volumes were assessed to determine Total Lesion Glycolysis (TLG). The tumor metabolic response (?SUVmax and ?TLG) was calculated. RESULTS: In univariate analysis, negative hormonal receptor status (p?=?0.04), high tumor grade (p?=?0.03), and low tumor PET?.SUVmax (p?=?0.001) were predictive of pCR. Tumor ?SUVmax correlated with pCR (p?=?0.03), provided that tumors with low metabolic activity at baseline were excluded. ?TLG did not correlate with pCR. In multivariate analysis, tumor PET?.SUVmax? |
| Publication | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 41 |
| Issue | 8 |
| Pages | 1525-1533 |
| Date | Aug 2014 |
| Journal Abbr | Eur. J. Nucl. Med. Mol. Imaging |
| Language | eng |
| DOI | 10.1007/s00259-014-2739-1 |
| ISSN | 1619-7089 |
| Short Title | HER2-positive breast cancer |
| Library Catalog | PubMed |
| Extra | PMID: 24647576 |
| Tags | Adult, Antibodies, Monoclonal, Humanized, Breast Neoplasms, Bridged-Ring Compounds, Carcinoma, Ductal, Breast, clinic, Female, Fluorodeoxyglucose F18, Genes, erbB-2, Humans, Middle Aged, Multimodal Imaging, Neoadjuvant Therapy, Positron-Emission Tomography, Predictive Value of Tests, Radiopharmaceuticals, Taxoids, Tomography, X-Ray Computed, Trastuzumab, Treatment Outcome |
| Date Added | 2019/05/28 - 17:28:47 |
| Date Modified | 2019/05/29 - 12:16:38 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
